Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Abstract: Provided are optimized humanized antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. In particular, the antibodies bind to particular epitopes outside the catalytic triad of the active site of human activated protein C. Methods of treatment employing these antibodies are described herein.

Abstract: Peptides of Formula I are useful for therapeutic purposes, among others.

Abstract: The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.

Abstract: The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.

Abstract: Peptides of Formula I are useful for therapeutic purposes, among others.

Abstract: A crystal comprising an androgen receptor ligand binding domain (AR-LBD) is provided. The crystal structures of the human Androgen Receptor Ligand Binding Domain (hAR-LBD) in comparison with the human Progesterone Receptor Ligand Binding Domains (hPR-(hPR-LBD) complexed with the same ligand metribolone (R1881) are also provided. The three-dimensional structures of the hAR LBD as well as the hPR LBD show the typical nuclear receptor fold. The change of two residues in the ligand binding pocket (LBP) between hPR and hAR seems to be the most likely source for the specificity of the R1881 ligand binding to hAR LBD. The structural implications of the 14 known mutations in the LBP of the hAR LBD associated with either prostate cancer (PC) or the partial androgen receptor insensitivity syndrome (PAIS) or complete androgen receptor insensitivity syndrome (CAIS) are analysed. The effects of most of these mutants may be explained on the basis of the crystal structure.

Abstract: The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.